13th Annual Leadership Awards Dinner

April 29, 2014

The Ritz-Carlton
Washington, DC

RECOGNIZING OUTSTANDING CONTRIBUTIONS TOWARDS HEALTH EQUITY
Novartis is honored to support the National Minority Quality Forum

From cancer to heart disease to rare disorders affecting smaller populations, Novartis Pharmaceuticals Corporation is proud to be the innovative force that’s bringing new optimism and hope to patients and their families. No one can promise what the future holds for any individual patient, but today millions are winning the fight against their particular diseases, and enjoying life to the fullest.

Novartis Pharmaceuticals Corporation is committed to embracing and leveraging diverse backgrounds, cultures and talents to address patients’ unmet medical needs.

To learn more, visit pharma.us.novartis.com
DEAR COLLEAGUES:

Welcome to the 2014 Annual Leadership Awards Dinner. This evening we are honoring the lifetime achievements of two individuals whose careers are exemplars of the potential, the essence, of public service.

Senator Ben Cardin (D-Maryland) has represented the people of the State of Maryland on Capitol Hill for almost 30 years, starting in 1987 in the U.S. House of Representatives, and continuing since 2006 in the U.S. Senate. Throughout his career, his commitment to health equity for all has been unstinting and unqualified. We look forward to continuing to work with him for many years to come.

John Ruffin, PhD, retired last month after nearly 24 years at the National Institutes of Health. His leadership on minority health research began with the Office of Minority Health Programs, and continued through the creation of the National Institute on Minority Health and Health Disparities. Dr. Ruffin takes with him to his retirement that rare gift – the knowledge that his vision of a national research agenda on minority health and health disparities was realized on his watch.

Thank you for your support of this shared event for the past eight years. The partnership between the Congressional Black Caucus Health Braintrust and the National Minority Quality Forum has been an exceptionally rewarding journey, both professionally and personally.

We both look forward to continuing our work with you all as we design a health services research, delivery and financing system that embodies the reality of health equity in the United States.

Sincerely,

Donna M. Christensen, MD (D-VI)  Gary A. Puckrein, PhD
Member of Congress  President and CEO
Chair, CBC Health Braintrust  National Minority Quality Forum
THANK YOU TO OUR 2014 SPONSORS
WELCOME
Master of Ceremonies
John Brockington

INVOCATION

OPENING REMARKS
Congresswoman Donna M. Christensen
Gary A. Puckrein, PhD
Barbara L. McAneny, MD

PRESENTATION OF HONOREE
Lifetime Achievement Award
John Ruffin, PhD

SPEAKER
William W. Chin, MD

SPEAKER
Gary A. Puckrein, PhD

ACKNOWLEDGMENT AND CLOSING REMARKS
Congresswoman Donna M. Christensen
Gary A. Puckrein, PhD

DINNER
Clinical trials are the most important way to evaluate the safety and efficacy of new medicines. We also know that ethnicity, lifestyle and genetics affect how medicines work in individual patients. But less than 17 percent of participants in trials today represent minority populations. It's our responsibility to help close the gap. By 2060, minorities will make up 57 percent of the U.S. population. We need more diverse representation in clinical trials to ensure treatments are safe and effective for all the people who use them. And we need your help.

For more information, or to learn about becoming an investigator, call 1-877-CTLILLY. Or, visit impact.nmanet.org.


We’re trying to treat MARIA. So why are we only testing medications on MARY?
National Minority Health Month

The National Minority Quality Forum (formerly the National Minority Health Month Foundation) was instrumental in launching National Minority Health Month, supported by a resolution from the U.S. Congress and recognized by many states. The Concurrent Resolution (H. Con. Res. 388) signed by the U.S. Congress on October 3, 2002, states that “a National Minority Health and Health Disparities Month should be established to promote educational efforts on the health problems facing minorities and other health disparity populations” and that “the President should issue a proclamation recognizing the immediate need to reduce health disparities in the United States and encouraging all health organizations and Americans to conduct appropriate programs and activities to promote healthfulness in minority and other health disparity communities.” National Minority Health Month is an inclusive initiative that addresses the health needs of African Americans, Hispanics, Asians, Native Americans, and other minorities. Its goal is to strengthen the capacity of local communities to eliminate the disproportionate burden of premature death and preventable illness in minority populations through prevention, early detection, and control of disease complications.
We’re here for a reason.

To transform lives by transforming medicine.

At Onyx, this is the guiding principle that drives both our scientific innovation and our dedication to deliver novel therapies to patients with life-threatening diseases.

LEARN MORE AT onyx.com
Barbara L. McAneny, MD, a board-certified medical oncologist/hematologist from Albuquerque, N.M., was elected to the American Medical Association Board of Trustees in June 2010. Her many leadership roles have included president of the New Mexico Medical Society (NMMS), president of the Greater Albuquerque Medical Association, and president of the New Mexico Chapter of the American College of Physicians. Dr. McAneny was appointed by Health and Human Services Secretary Tommy Thompson to the Practicing Physicians Advisory Council from 2002 to 2006.

She was a founding member of Oncology Circle, an organization of oncology practices using data to promote best practices. She has served on the board of directors of the Cancer Center Business Summit. She has championed numerous health-related issues including tobacco-use prevention, professional liability reform and emergency medical services (EMS). In 2012 Dr. McAneny was awarded a $19.8 million grant from the Centers for Medicare & Medicaid Innovation to test how oncology private practices can provide cancer patients better care at a lower cost. A recipient of a New Mexico Woman on the Move Award in 2005 and Woman of Influence Award in 2009, Dr. McAneny has been voted several times by her peers as Albuquerque The Magazine’s “Top Doc” in her specialty.

She co-founded Oncology Hematology Consultants Ltd. in 1987. A managing partner since 1999, she built New Mexico Cancer Center, which provides comprehensive outpatient medical and radiation oncology care and imaging at multiple sites, including several underserved rural areas. She also founded the New Mexico Cancer Center Foundation, which provides grants to patients to help with their nonmedical expenses and to health care professionals and patients for continuing education.

Dr. McAneny graduated magna cum laude from the University of Minnesota in 1973, and with honors from the University of Iowa College of Medicine in 1977. She completed her residency in internal medicine at the University of Iowa in 1980 and her fellowship in hematology/oncology at the University of New Mexico in 2003.
Leadership... It’s time to think differently about what a pharmaceutical company can be. Novo Nordisk has dedicated itself to defeating diabetes, which is an interesting goal given that diabetes is the primary focus of our business.

Changing Diabetes™ means helping people with our actions, and not just with our products. It means staying true to our ideals and being respectful of the world we live in. And it means continuing to dedicate significant resources to diabetes research until a cure is found.

With leadership comes responsibility. We are committed to improving options for care now while partnering with others who share our mission and ultimate goal of defeating this disease.
Senator Ben Cardin of Maryland believes government has a duty to improve the lives of all Americans. From expanding access to health care to boosting job growth to making homeownership affordable to improving the environment, Senator Cardin is a recognized leader with a record of legislative success.

First elected to the U.S. Senate in 2006, he was re-elected in 2012. Senator Cardin currently serves on the Finance, Foreign Relations, Environment and Public Works, and Small Business committees.

The Washington Post has said Ben Cardin has a “command of issues, proven integrity, formidable intellect and an unstinting work ethic.”

Senator Cardin believes access to quality, affordable health care is a right. He was a strong supporter of the Affordable Care Act, which will provide more than 30 million uninsured Americans with health coverage. In the wake of the death of a 12-year-old Marylander from an untreated tooth infection, he successfully fought to get a guaranteed dental benefit included in the Children’s Health Insurance Program.

As a member of the Small Business Committee, Senator Cardin has championed legislation to permanently raise the surety bond guarantee limit from $2 million to $6.5 million and adjust it for inflation.

He also has been a strong defender of the federal workforce. He believes that federal workers have already made a significant contribution to reducing the deficit with a pay freeze and does not believe they should shoulder the burden of deficit reduction alone.

He also is a strong champion of protecting our air and water. He has introduced legislation to restore the health of America’s great water bodies – including the Chesapeake Bay. And, he has fought for funding to improve America’s aging water infrastructure system, which would create thousands of new jobs.

In the Senate, Ben Cardin brings the expertise he developed while serving in the House of Representatives. Known for his command of pension and health care legislation, many of his financial proposals have been enacted into law, including: increasing the amount Americans can save for retirement and expanding Medicare to include preventive benefits.
And indeed, for over 85 years, Otsuka’s people have achieved major milestones in their quest to create new products for better health. Otsuka is hard at work investigating potential new treatments, with numerous compounds in various stages of development to treat disorders of the cardiovascular, gastrointestinal, respiratory, renal, and central nervous systems, and to treat cancer and ophthalmic disorders. We’ve funded new research, supported new clinical trials, and pursued the development of new medications – an unfaltering commitment of energy and resources with one goal in mind – to create new products for better health worldwide.
Boehringer Ingelheim ranks among the world’s 20 leading pharmaceutical corporations. Our vision drives us forward. It helps us to foster value through innovation in our company and to look to the future with constantly renewed commitment and ambition.

Boehringer Ingelheim is proud to be a participant in the NMQF/PhRMA “I’m In” campaign. We believe in the value of Making More Health for our patients. We celebrate our industry’s commitment to improving education, diversity and inclusion in clinical trials.

Visit us online at us.boehringer-ingelheim.com
Peritoneal dialysis can provide ESRD patients a strong foundation for Renal Replacement Therapy (RRT).
Dr. John Ruffin recently retired as the Director of the National Institute on Minority Health and Health Disparities (NIMHD) of the National Institutes of Health (NIH). He oversaw the NIMHD budget of approximately $276 million. In addition, he provided leadership for the minority health and health disparities research activities of the NIH which constitutes an annual budget of approximately $2.8 billion.

Dr. Ruffin is a well-respected leader and visionary in the field of minority health and health disparities. As an academician and a scientist, he has devoted his professional career to improving the health status of racial and ethnic minorities and other underserved populations. He has an impressive track record of developing and supporting programs to increase the cadre of minority scientists, physicians, and other health professionals, as well as attract a diverse group of researchers to the health disparities field.

The hallmark of his career has been his success in leading the transformation of the NIH minority health and health disparities research agenda from a programmatic concept to an institutional reality. Today, the National Institute on Minority Health and Health Disparities (NIMHD) is leading the way in facilitating cross-agency collaboration among federal government agencies and private partnerships to integrate science, policy, practice and community efforts toward eliminating health disparities. As the NIH federal official for minority health disparities research, Dr. Ruffin has planned and brought to fruition the largest biomedical research program in the nation aimed at efforts to eliminate health disparities.

Dr. Ruffin has a stellar record of professional achievement including numerous honorary degrees. He is a recipient of the Cura Personalis Award from Georgetown University Medical Center. He has also received the Martin Luther King, Jr. Legacy Award for National Service, the Department of Health and Human Services’ Special Recognition Award, and the U.S. Presidential Merit Award.

Dr. Ruffin received a BS in Biology from Dillard University, an MS in Biology from Atlanta University, a PhD in Systematic and Developmental Biology from Kansas State University, and completed post-doctoral studies in biology at Harvard University.
Increased diversity in clinical trials could help researchers find better ways to fight diseases that disproportionately impact certain populations.

*I’m In* is a campaign designed to improve health by increasing clinical trial participation among traditionally underrepresented populations, including African Americans, Asian Americans and Hispanics.

*Together we can make a difference.*

*Are you in?*
Dr. William W. Chin is the Executive Vice President of Scientific and Regulatory Affairs at PhRMA where he leads efforts in science advocacy in the drug discovery and development ecosystem.

He was previously the Executive Dean for Research, Bertarelli Professor of Translational Medical Science and Professor of Medicine at Harvard Medical School (HMS). In that role, Dr. Chin spearheaded efforts to design and implement the vision for research, with special emphasis on interdisciplinary and translational research that crossed departmental and institutional boundaries.

Prior to HMS, Dr. Chin was the senior vice president for Discovery Research and Clinical Investigation at Eli Lilly and Company.

He received his AB from Columbia University and his MD from Harvard Medical School.
LOVE IS THE MOST POWERFUL THING ON THE PLANET.

Love is in a baby’s first smile.
In a grandmother’s comforting touch.
And in all the wonderful moments in between.

Love rearranges our priorities.
It makes us want to give,
expecting nothing in return.

Love is the reason you care.

For the tiny and the fragile.
For the wise and irreplaceable.

For all the things in your life
that make life worth living.

Johnson & Johnson
for all you love
Thank You

CONGRESSWOMAN DONNA M. CHRISTENSEN

The National Minority Quality Forum congratulates Congresswoman Donna M. Christensen on a distinguished and courageous career in the U.S. Congress. Although your official role has been as the Delegate from the Virgin Islands, your leadership of the CBC Health Braintrust has enabled you to have a positive effect on the lives of all Americans.

It has been our honor to work with you in partnership and in friendship!

Sincerely,

The National Minority Quality Forum
Jeffery Berry        David Elwell
William Griffith    Margo Payne
Gretchen C. Wartman Liou Xu
Gary A. Puckrein
DO YOU KNOW THE FIBS OR FACTS ABOUT AFIB RELATED STROKE?

Howie Mandel is a comedian, actor, and game show host, and is a paid spokesperson for Bristol-Myers Squibb and Pfizer.

Atrial fibrillation (AFib), a type of irregular heartbeat, not caused by a heart valve problem affects approximately 5.8 million people in the U.S. — like me. AFib not caused by a heart valve problem puts people at a 5 times greater risk for stroke.

WHY DOES HOWIE MANDEL CARE ABOUT AFIB?

“Even game show hosts don’t know everything. When my doctor told me I had AFib not caused by a heart valve problem, I had no idea that I was at an increased risk of stroke. Now, I want to be sure others know about this serious condition, so I am challenging everyone to test their knowledge by completing a quiz at FibsorFacts.com.”
Pfizer is proud to support National Minority Quality Forum
The American Medical Association is pleased to participate in the National Minority Quality Forum (NMQF) health disparities summit.

We are pleased to be partners with the NMQF in improving health outcomes in all patient populations.

Visit ama-assn.org/go/mas or call (312) 464-4335 to find out how you can take advantage of our diverse resources, programs and initiatives.
Alkermes plc is a fully integrated biotechnology company that uses proprietary technologies and know-how to create innovative medicines designed to yield better therapeutic outcomes for patients with serious diseases, including central nervous system disorders, addiction and diabetes.

For more information about Alkermes, please visit: www.alkermes.com
MEDICAL BREAKTHROUGHS MAY COME OUT OF THE LAB.
BUT THEY BEGIN IN THE HEART.

For more than 150 years, a very special passion has driven the people of Merck. Our goal is to develop medicines, vaccines, consumer care and animal health innovations that will improve the lives of millions. Still, we know there is much more to be done. And we’re doing it, with a long-standing commitment to research and development. We’re just as committed to expanding access to healthcare and working with others who share our passion to create a healthier world. Together, we’ll meet that challenge. With all our heart.

For more information about getting Merck medicines and vaccines for free, visit merckhelps.com or call 800-727-5400.
With more than 30 years of experience, Roche, the maker of ACCU-CHEK® products, is committed to helping improve the care and outcomes of patients locally, regionally and worldwide.

BRINGING it all TOGETHER

With more than 30 years of experience, Roche, the maker of ACCU-CHEK® products, is committed to helping improve the care and outcomes of patients locally, regionally and worldwide.

patient engagement

therapy optimization

practice efficiency

ACCU-CHEK is a trademark of Roche. © 2013 Roche. 308-52375-0413
The Black Women’s Health Imperative serves the 20 million Black women and girls across the nation. Through the Imperative lens, we envision a world where every Black woman and girl can achieve her optimum health—physically, emotionally and financially.

We applaud the work of the National Minority Quality Forum and the 2014 CBC Spring Health Braintrust for the Annual Health Disparities Leadership Summit.
AstraZeneca is proud to support NMQF
RECOGNIZING OUTSTANDING CONTRIBUTIONS TOWARDS HEALTH EQUITY

1200 New Hampshire Avenue, NW • Suite 575
Washington, DC 20036
tel 202.223.7560 • fax 202.223.7567
www.nmqf.org